natgillin/translations-raw huggingface dataset:
I de kliniske studier er der rapporteret om følgende bivirkninger, som er opstillet efter hyppighed i henhold til denne konvention: meget almindelig (> 1/ 10); almindelig (> 1/ 100 til < 1/ 10), ikke almindelig (> 1/ 1. 000 til < 1/ 100); sjælden (> 1/ 10. 000 til < 1/ 1. 000); meget sjælden (< 1/ 10. 000); ikke kendt (kan ikke estimeres ud fra forhåndenværende data).
The following adverse effects or events have been reported during clinical trials and are ranked using the following frequency: very common (> 1/ 10); common (> 1/ 100 ,< 1/10); uncommon (> 1/1000 ,< 1/100); rare (> 1/ 10000 ,< 1/1000); very rare (< 1/10000); not known (cannot be estimated from the available data).
- Hyperurikæmi
- Hyperuricaemia
- Eosinofili
- Eosinophilia
- Forhøjet kreatinin i blodet
- Elevated creatinine in blood
Hjerte Almindelig:
Cardiac disorders:
- Bradykardi:
- Bradycardia:
3, 3% af patienterne, specielt inden for de første to til tre måneders behandling.
3.3% of patients particularly within the first 2 to 3 months of treatment initiation.
0, 5% af patienterne fik svær bradykardi under eller svarende til 40 slag/ min
0.5% of patients experienced a severe bradycardia below or equal to 40 bpm.
- 1. grads AV- blok.
- AV 1st degree block
- Ventrikulære ekstrasystoler.
- Ventricular extrasystoles
Ikke almindelig:
6 Uncommon:
- Palpitationer, supraventrikulære ekstrasystoler
- Palpitations, supraventricular extrasystoles
6 angina pectoris, accelereret angina pectoris, atrieflimren, myokardial iskæmi, myokardieinfarkt og ventrikulær takykardi.
The following events reported during clinical trials were of similar incidence than comparators and/ or possibly related to the underlying disease: sinus arrhythmia, unstable angina, angina pectoris aggravated, atrial fibrillation, myocardial ischaemia, myocardial infarction and ventricular tachycardia.
Rapporteret af 14, 5% af patienterne og beskrevet som et forbigående
- Luminous phenomena (phosphenes): reported by 14.5% of patients, described as a transient
lysglimt i en begrænset del af synsfeltet.
enhanced brightness in a limited area of the visual field.
Symptomerne udløses normalt af pludselige variationer i lysintensiteten.
They are usually triggered by sudden variations in light intensity.
Starten på fosfener sker generelt inden for de første to behandlingsmåneder, hvorefter de kan optræde gentagne gange.
The onset of phosphenes is generally within the first two months of treatment after which they may occur repeatedly.
Fosfener blev generelt rapporteret at være lette eller moderate.
Phosphenes were generally reported to be of mild to moderate intensity.
Alle fosfener forsvandt under eller efter behandlingen, de fleste (77, 5%) dog under behandlingen.
All phosphenes resolved during or after treatment, of which a majority (77.5%) resolved during treatment.
Mindre end 1% af patienterne måtte ændre deres daglige rutine eller stoppe behandlingen på grund af fosfener.
Fewer than 1% of patients changed their daily routine or discontinued the treatment in relation with phosphenes.
- Uskarpt syn
- Blurred vision
- Obstipation
- Constipation
- Diarre
- Diarrhoea
- Hovedpine, almindeligvis i den første behandlingsmåned.
- Headache, generally during the first month of treatment.
- Svimmelhed, muligvis relateret til bradykardi.
- Dizziness, possibly related to bradycardia.
- Dyspnø
- Dyspnoea
- Muskelkramper
- Muscle cramps
Overdosering kan medføre svær og forlænget bradykardi (se pkt.
Overdose may lead to severe and prolonged bradycardia (see section 4.8).
Hvis der optræder bradykardi med dårlig hæmodynamisk tolerans, kan symptomatisk behandling, inklusive intravenøs behandling med β- stimulerende stoffer som fx isoprenalin, overvejes.
In the event of bradycardia with poor haemodynamic tolerance, symptomatic treatment including intravenous beta- stimulating agents such as isoprenaline may be considered.
Farmakoterapeutisk klassifikation: andre hjertepræparater, ATC- kode:
Pharmacotherapeutic group: other cardiac preparations, ATC code:
De kardiale virkninger er specifikke for sinusknuden og uden effekt på hverken de intra- atriale, atrioventrikulære eller intraventrikulære overledningstider eller på den myokardiale kontraktilitet eller den ventrikulære repolarisering.
The cardiac effects are specific to the sinus node with no effect on intra-atrial, atrioventricular or intraventricular conduction times, nor on myocardial contractility or ventricular repolarisation.
Ivabradin kan interagere med den retinale jonkanalstrøm Ih, som ligner den kardiale If meget.
7 Ivabradine can interact also with the retinal current Ih which closely resembles cardiac If.
7 lejlighedsvis opleves af patienterne, ivabradins partielle hæmning af Ih.
Under triggering circumstances (e. g. rapid changes in luminosity), partial inhibition of Ih by ivabradine underlies the luminous phenomena that may be occasionally experienced by patients.
4. 8).
Luminous phenomena (phosphenes) are described as a transient enhanced brightness in a limited area of the visual field (see section 4.8).
4. 8).
Analysis of heart rate reduction with doses up to 20 mg twice daily indicates a trend towards a plateau effect which is consistent with a reduced risk of severe bradycardia below 40 bpm (see section 4.8).
10 slag/ min i hvile og under arbejde.
At usual recommended doses, heart rate reduction is approximately 10 bpm at rest and during exercise.
Ivabradin påvirker ikke den intrakardiale overledning, kontraktiliteten (ingen negativ inotrop effekt) eller den ventrikulære repolarisering:
Ivabradine does not influence intracardiac conduction, contractility (no negative inotropic effect) or ventricular repolarisation:
- I kliniske elektrofysiologiske studier havde ivabradin ingen effekt på de atrioventrikulære eller
- in clinical electrophysiology studies, ivabradine had no effect on atrioventricular or intraventricular
intraventrikulære overledningstider eller de korrigerede QT- intervaller.
conduction times or corrected QT intervals;
- Hos patienter med dysfunktion af venstre ventrikel (venstre ventrikulære uddrivningsfraktion
- in patients with left ventricular dysfunction (left ventricular ejection fraction (LVEF) between 30
(LVEF) mellem 30 og 45%) havde ivabradin ingen negativ indflydelse på LVEF.
and 45%), ivabradine did not have any deleterious influence on LVEF.
Virkningen af Corlentor på angina pectoris og iskæmi blev undersøgt i fire dobbeltblinde randomiserede studier (to versus placebo og et versus hhv. atenolol og amlodipin).
The antianginal and anti-ischaemic efficacy of Corlentor was studied in four double-blind randomised trials (two versus placebo, and one each versus atenolol and amlodipine).
Studierne inkluderede 3222 patienter med kronisk stabil angina pectoris, hvoraf 2168 fik ivabradin.
These trials included a total of 3,222 patients with chronic stable angina pectoris, of whom 2,168 received ivabradine.
Effekten blev bekræftet med 7, 5 mg to gange daglig.
Efficacy was confirmed with 7.5 mg twice daily.
1 minut efter en måneds behandling med 5 mg to gange daglig og yderligere forbedret med næsten 25 sek. efter yderligere 3 måneder med tvungen stigning til 7, 5 mg to gange daglig.
In particular, the additional benefit over 5 mg twice daily was established in a reference-controlled study versus atenolol: total exercise duration at trough was increased by about 1 minute after one month of treatment with 5 mg twice daily and further improved by almost 25 seconds after an additional 3-month period with forced titration to 7.5 mg twice daily.
70% i antallet af anginaanfald.
The efficacy of 5 and 7.5 mg twice daily was consistent across studies on exercise test parameters (total exercise duration, time to limiting angina, time to angina onset and time to 1mm ST segment depression) and was associated with a decrease of about 70% in the rate of angina attacks.
I et randomiseret, placebokontrolleret studie, som omfattede 725 patienter, forårsagede ivabradin, givet som adjuvans til amlodipin, ingen yderligere effekt ved på tidspunktet for minimal aktivitet (12 timer efter oral indtagelse), hvorimod der observeredes yderligere effekt på tidspunktet for maksimal aktivitet (3- 4 timer efter oral indtagelse).
In a 725-patients randomised placebo-controlled study, ivabradine did not show additional efficacy on top of amlodipine at the trough of drug activity (12 hours after oral intake) while an additional efficacy was shown at peak (3-4 hours after oral intake).
I effektstudierne opretholdtes den fulde effekt af ivabradin under hele behandlingsforløbet på 3- 4 måneder.
Ivabradine efficacy was fully maintained throughout the 3- or 4-month treatment periods in the efficacy trials.
Der var ikke tegn på udvikling af farmakologisk tolerans (tab af effekt) under behandlingen og heller ikke på rebound- fænomener efter abrupt afbrydelse af behandlingen.
There was no evidence of pharmacological tolerance (loss of efficacy) developing during treatment nor of rebound phenomena after abrupt treatment discontinuation.
Hos patienter, som blev behandlet med ivabradin i mindst et år (n = 713), dokumenteredes et vedvarende fald i hjertefrekvensen. = Der blev ikke set påvirkning af glukose - eller lipidmetabolismen.
No influence on glucose or lipid metabolism was observed.
Under fysiologiske betingelser frigøres ivabradin hurtigt fra tabletterne og er letopløseligt i vand (> 10 mg/ ml).
5.2 Pharmacokinetic properties 8 Under physiological conditions, ivabradine is rapidly released from tablets and is highly water-soluble (> 10 mg/ ml).
Ivabradin er S- enantiomeren, og der er ikke påvist bioomdannelse in vivo.
Ivabradine is the S-enantiomer with no bioconversion demonstrated in vivo.
Det N- demetylerede derivat af ivabradin er identificeret som den aktive hovedmetabolit hos mennesker.
The N- desmethylated derivative of ivabradine has been identified as the main active metabolite in humans.
1 time under fastende betingelser.
Absorption and bioavailability Ivabradine is rapidly and almost completely absorbed after oral administration with a peak plasma level reached in about 1 hour under fasting condition.
40% på grund af en førstepassage- effekt i tarm og lever.
The absolute bioavailability of the film-coated tablets is around 40%, due to first-pass effect in the gut and liver.
1 time og øgede plasmaeksponering med 20- 30%.
Food delayed absorption by approximately 1 hour, and increased plasma exposure by 20 to 30%.
4. 2).
The intake of the tablet during meals is recommended in order to decrease intra-individual variability in exposure (see section 4.2).
70% bundet til plasmaproteiner, og fordelingsvolumenet i steady- state er næsten 100 l hos patienter.
Distribution Ivabradine is approximately 70% plasma protein bound and the volume of distribution at steady-state is close to 100 l in patients.
22 ng/ ml (CV = 29%).
The maximum plasma concentration following chronic administration at the recommended dose of 5 mg twice daily is 22 ng/ ml (CV=29%).
Den gennemsnitlige plasmakoncentration i steady- state er 10 ng/ ml (CV = 38%).
The average plasma concentration is 10 ng/ ml (CV=38%) at steady-state.
Biotransformation Ivabradin undergår en omfattende metabolisering i leveren og tarmen ved oxidation, udelukkende ved hjælp af cytokrom P450 3A4 (CYP3A4).
Biotransformation Ivabradine is extensively metabolised by the liver and the gut by oxidation through cytochrome P450 3A4 (CYP3A4) only.
40% af moderstoffets eksponering.
The major active metabolite is the N-desmethylated derivative (S 18982) with an exposure about 40% of that of the parent compound.
Ivabradin har lav affinitet til CYP3A4, viser ingen klinisk relevant induktion eller hæmning af CYP3A4 - og vil derfor sandsynligvis ikke modificere metabolismen af CYP3A4- substrater eller deres plasmakoncentrationer.
Ivabradine has low affinity for CYP3A4, shows no clinically relevant CYP3A4 induction or inhibition and is therefore unlikely to modify CYP3A4 substrate metabolism or plasma concentrations.
4. 5).
Inversely, potent inhibitors and inducers may substantially affect ivabradine plasma concentrations (see section 4.5).
Elimination Ivabradin udskilles med en hovedhalveringstid på 2 timer (70- 75% af AUC) i plasma og en effektiv eliminationshalveringstid på 11 timer.
Elimination Ivabradine is eliminated with a main half-life of 2 hours (70-75% of the AUC) in plasma and an effective half-life of 11 hours.
70 ml/ min.
The total clearance is about 400 ml/ min and the renal clearance is about 70 ml/ min.
Ca.
Excretion of metabolites occurs to a similar extent via faeces and urine.
4% af en peroral dosis udskilles uomdannet med urinen.
About 4% of an oral dose is excreted unchanged in urine.
Linearitet/ non- linearitet Ivabradins kinetik er lineær over en peroral dosisspændvidde på 0, 5 – 24 mg.
Linearity/ non linearity The kinetics of ivabradine is linear over an oral dose range of 0.5 – 24 mg.
Der er ikke observeret farmakokinetiske forskelle (AUC og Cmax) mellem ældre (≥ 65 år)
- Elderly: no pharmacokinetic differences (AUC and Cmax) have been observed between elderly (≥
4. 2).
65 years) or very elderly patients (≥ 75 years) and the overall population (see section 4.2).
Påvirkningen af nedsat nyrefunktion (kreatininclearance fra 15 til 60 ml/ min) på
- Renal insufficiency: the impact of renal impairment (creatinine clearance from 15 to 60 ml/ min) on
4. 2).
ivabradine pharmacokinetic is minimal, in relation with the low contribution of renal clearance (about 20%) to total elimination for both ivabradine and its main metabolite S 18982 (see section 4.2).
Hos patienter med let leverinsufficiens (Child- Pugh Score op til 7) var AUC for
- Hepatic impairment: in patients with mild hepatic impairment (Child Pugh score up to 7) unbound
20% større end hos patienter med normal leverfunktion.
AUC of ivabradine and the main active metabolite were about 20% higher than in subjects with normal hepatic function.
4. 2 og 4. 3).
No data are available in patients with severe hepatic impairment (see sections 4.2 and 4.3).
Farmakokinetisk/ farmakodynamisk (PK/ PD) sammenhæng Analyse af PK/ PD- forholdet har vist, at hjertefrekvensen falder næsten lineært med stigende plasmakoncentrationer af ivabradin og S 18982 i doser op til 15- 20 mg to gange daglig.
Pharmacokinetic/ pharmacodynamic (PK/ PD) relationship PK/ PD relationship analysis has shown that heart rate decreases almost linearly with increasing ivabradine and S 18982 plasma concentrations for doses of up to 15-20 mg twice daily.
4. 3, 4. 4 og 4. 5).
High exposures to ivabradine that may occur when ivabradine is given in
9 5. 3 Prækliniske sikkerhedsdata
9 combination with strong CYP3A4 inhibitors may result in an excessive decrease in heart rate although this risk is reduced with moderate CYP3A4 inhibitors (see sections 4.3, 4.4 and 4.5).
Reproduktionstoksikologiske studier viste ingen effekt af ivabradin på fertiliteten hos han - og hunrotter.
Reproductive toxicity studies showed no effect of ivabradine on fertility in male and female rats.
Hos hund førte ivabradindoser på 2, 7 eller 24 mg/ kg/ dag i et år til observation af reversible forandringer i retinafunktionen, men var ikke forbundet med skader i okulære strukturer.
In dogs given ivabradine (doses of 2, 7 or 24mg/ kg/ day) for one year, reversible changes in retinal function were observed but were not associated with any damage to ocular structures.
Disse data er konsistente med den farmakologiske effekt af ivabradin, relateret til dets interaktion med hyperpolarisations- aktiverede Ih jonkanalstrømme i retina, som har omfattende fælles homologi med den kardiale pacemaker If jonkanalstrøm.
These data are consistent with the pharmacological effect of ivabradine related to its interaction with hyperpolarisation-activated Ih currents in the retina, which share extensive homology with the cardiac pacemaker If current.
Kerne Lactosemonohydrat Magnesiumstearat (E470 B) Majsstivelse Maltodextrin Silica, kolloid vandfri (E551)
Core Lactose monohydrate Magnesium stearate (E 470 B) Maize starch Maltodextrin Silica, colloidal anhydrous (E 551)
Filmovertræk Hypromellose (E464) Titandioxid (E171) Macrogol 6000 Glycerol (E422) Magnesiumstearat (E470 B) Gul jernoxid (E172) Rød jernoxid (E172)
Film-coating Hypromellose (E 464) Titanium dioxide (E171) Macrogol 6000 Glycerol (E 422) Magnesium stearate (E 470 B) Yellow iron oxide (E172) Red iron oxide (E172)
Aluminium/ PVC- blister pakket i papkartoner.
Aluminium/ PVC blister packed in cardboard boxes.
Pakningsstørrelser Kalenderpakninger indeholdende 14, 28, 56, 84, 98, 100 eller 112 filmovertrukne tabletter.
Pack sizes Calendar packs containing 14, 28, 56, 84, 98, 100 or 112 film-coated tablets.
10 6. 6 Regler for destruktion
10 6.6 Special precautions for disposal
Les Laboratoires Servier 22 rue Garnier F- 92200 Neuilly sur Seine Frankrig
Les Laboratoires Servier 22 rue Garnier 92200 Neuilly sur Seine France
Corlentor 7, 5 mg filmovertrukne tabletter
Corlentor 7.5 mg film-coated tablets
En filmovertrukken tablet indeholder 7, 5 mg ivabradin (ækvivalent med 8, 085 mg ivabradinhydrochlorid).
One film-coated tablet contains 7.5 mg ivabradine (equivalent to 8.085 mg ivabradine as hydrochloride).
6. 1.
61.215 mg lactose monohydrate For a full list of excipients, see section 6.1.
Laksefarvet, trekantet, filmovertrukken tablet, mærket med ” 7. 5 ” på den ene side og anden.
Salmon-coloured, triangular, film-coated tablet engraved with “ 7.5 ” on one face and face.
på den
on the other
12 Leverinsufficiens Dosisjustering er ikke nødvendig til patienter med mild leverinsufficiens.
12 Hepatic impairment No dose adjustment is required in patients with mild hepatic impairment.
- Kombination med stærke cytokrom P450 3A4- hæmmere som fx azol- antimykotika (ketoconazol,
- Combination with strong cytochrome P450 3A4 inhibitors such as azole antifungals
Kombination med andre midler mod angina pectoris Samtidig anvendelse af ivabradin med hjertefrekvenssænkende calciumantagonister som fx verapamil eller diltiazem kan ikke anbefales (se pkt.
13 Combination with other antianginal therapies Concomitant use of ivabradine with heart rate reducing calcium channel blockers such as verapamil or diltiazem is not recommended (see section 4.5).
14 4. 5 Interaktion med andre lægemidler og andre former for interaktion
14 4.5 Interaction with other medicinal products and other forms of interaction
15 calciumantagonister (amlodipin, lacidipin), digoxin og warfarin.
15 Other concomitant use Specific drug-drug interaction studies have shown no clinically significant effect of the following medicinal products on pharmacokinetics and pharmacodynamics of ivabradine: proton pump inhibitors (omeprazole, lansoprazole), sildenafil, HMG CoA reductase inhibitors (simvastatin), dihydropyridine calcium channel blockers (amlodipine, lacidipine), digoxin and warfarin.
I de kliniske studier er der rapporteret om følgende bivirkninger, som er opstillet efter hyppighed i henhold til denne konvention: meget almindelig (> 1/ 10); almindelig (> 1/ 100 til < 1/ 10), ikke almindelig (> 1/ 1. 000 til < 1/ 100); sjælden (> 1/ 10. 000 til < 1/ 1. 000); meget sjælden (< 1/ 10. 000); ikke kendt (kan ikke estimeres ud fra forhåndenværende data)
The following adverse effects or events have been reported during clinical trials and are ranked using the following frequency: very common (> 1/ 10); common (> 1/ 100 ,< 1/10); uncommon (> 1/1000 ,< 1/100); rare (> 1/ 10000 ,< 1/1000); very rare (< 1/10000); not known (cannot be estimated from the available data).
16 angina pectoris, accelereret angina pectoris, atrieflimren, myokardial iskæmi, myokardieinfarkt og ventrikulær takykardi.
16 Uncommon:
Ivabradin kan interagere med den retinale jonkanalstrøm Ih, som ligner den kardiale If meget.
17 Ivabradine can interact also with the retinal current Ih which closely resembles cardiac If.
17 lejlighedsvis opleves af patienterne, ivabradins partielle hæmning af Ih.
Under triggering circumstances (e. g. rapid changes in luminosity), partial inhibition of Ih by ivabradine underlies the luminous phenomena that may be occasionally experienced by patients.
Under fysiologiske betingelser frigøres ivabradin hurtigt fra tabletterne og er letopløseligt i vand (> 10 mg/ ml).
5.2 Pharmacokinetic properties 18 Under physiological conditions, ivabradine is rapidly released from tablets and is highly water-soluble (> 10 mg/ ml).
Det N- demethylerede derivat af ivabradin er identificeret som den aktive hovedmetabolit hos mennesker.
The N- desmethylated derivative of ivabradine has been identified as the main active metabolite in humans.
19 5. 3 Prækliniske sikkerhedsdata
19 combination with strong CYP3A4 inhibitors may result in an excessive decrease in heart rate although this risk is reduced with moderate CYP3A4 inhibitors (see sections 4.3, 4.4 and 4.5).
20 6. 6 Regler for destruktion
20 6.6 Special precautions for disposal
INDEHAVERE AF VIRKSOMHEDSGODKENDELSER ANSVARLIGE FOR BATCHFRIGIVELSE
22 A MANUFACTURING AUTHORISATION HOLDERS RESPONSIBLE FOR BATCH RELEASE
Les Laboratoires Servier Industrie, 905, route de Saran – F- 45520 Gidy, Frankrig Servier (Ireland) Industries Ltd, Gorey Road – Arklow – Co.
Les Laboratoires Servier Industrie, 905, route de Saran - 45520 Gidy, France Servier (Ireland) Industries Ltd, Gorey Road – Arklow – Co.
Wicklow, Irland Przedsiebiorstwo Farmaceutyczne ANPHARM S. A., ul.
Wicklow, Ireland Przedsiebiorstwo Farmaceutyczne ANPHARM S. A., ul.
Annopol 6B – PL- 03- 236 Warszawa, Polen
Annopol 6B – 03-236 Warszawa, Poland
25 OPLYSNINGER, DER SKAL ANFØRES PÅ DEN YDRE EMBALLAGE
25 PARTICULARS TO APPEAR ON THE OUTER PACKAGING {CARTON}
Corlentor 5 mg filmovertrukne tabletter ivabradin
Corlentor 5 mg film-coated tablets ivabradine
En filmovertrukket tablet indeholder 5 mg ivabradin (svarende til 5, 390 mg ivabradinhydrochlorid)
One film-coated tablet contains 5 mg ivabradine (equivalent to 5.390 mg ivabradine hydrochloride)
Les Laboratoires Servier 22, rue Garnier F- 92200 Neuilly- sur- Seine Frankrig
Les Laboratoires Servier 22, rue Garnier 92200 Neuilly-sur-Seine France
BLISTER
{BLISTER}
LOT {nummer}
LOT {number}
28 OPLYSNINGER, DER SKAL ANFØRES PÅ DEN YDRE EMBALLAGE
28 PARTICULARS TO APPEAR ON THE OUTER PACKAGING {CARTON}
Corlentor 7, 5 mg filmovertrukne tabletter ivabradin
Corlentor 7.5 mg film-coated tablets ivabradine
En filmovertrukket tablet indeholder 7, 5 mg ivabradin (svarende til 8, 085 mg ivabradinhydrochlorid)
One film-coated tablet contains 7.5 mg ivabradine (equivalent to 8.085 mg ivabradine hydrochloride)
30 MINDSTEKRAV TIL OPLYSNINGER PÅ BLISTERKORT ELLER BLISTERSTRIPS
30 MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS
INFORMATION TIL BRUGEREN Corlentor 5 mg filmovertrukne tabletter Corlentor 7, 5 mg filmovertrukne tabletter ivabradin
INFORMATION FOR THE USER Corlentor 5 mg film-coated tablets Corlentor 7.5 mg film-coated tablets ivabradine
- Lægen har ordineret Corlentor til Dem personligt.
- This medicine has been prescribed for you.
Lad derfor være med at give Corlentor til
It may harm them, even
Det kan være skadeligt for andre, selv om de har de samme symptomer, som De har.
if their symptoms are the same as yours.
- Tal med lægen eller apoteket, hvis en bivirkning bliver værre, eller De får bivirkninger, som
- If any of the side effects gets serious, or if you notice side effects not listed in this leaflet, please
ikke er nævnt her.
tell your doctor or pharmacist.
Corlentors virkning og hvad De skal bruge det til 2.
What Corlentor is and what it is used for 2.
Det skal De vide, før De begynder at tage Corlentor 3.
Before you take Corlentor 3.
Sådan skal De tage Corlentor 4.
How to take Corlentor 4.
Sådan opbevarer De Corlentor 6.
Possible side effects 5 How to store Corlentor 6.
CORLENTORS VIRKNING OG HVAD DE SKAL BRUGE DET TIL
WHAT CORLENTOR IS AND WHAT IT IS USED FOR
Corlentor er en hjertemedicin, som anvendes til behandling af stabil angina pectoris – en lidelse, som forårsager smerter i brystet - når betablokkere (som fx atenolol, propranolol og metoprolol til behandling af forhøjet blodtryk, hjerterytmeforstyrrelse eller angina pectoris) ikke kan anvendes.
Corlentor is a heart medicine used to treat stable angina pectoris which causes chest pain, when beta- blockers (like atenolol, propranolol, metoprolol, etc, for high blood pressure, heart rhythm disorders, or angina pectoris) are not suitable.